MsGoF: Breast lesion classification on ultrasound images by multi-scale gradational-order fusion framework.

Comput Methods Programs Biomed

School of Biomedical Engineering, Southern Medical University, Guangzhou 510515, China; Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, Guangzhou 510515, China; Guangdong Province Engineering Laboratory for Medical Imaging and Diagnostic Technology, Southern Medical University, Guangzhou 510515, China. Electronic address:

Published: March 2023

Background And Objective: Predicting the malignant potential of breast lesions based on breast ultrasound (BUS) images is a crucial component of computer-aided diagnosis system for breast cancers. However, since breast lesions in BUS images generally have various shapes with relatively low contrast and present complex textures, it still remains challenging to accurately identify the malignant potential of breast lesions.

Methods: In this paper, we propose a multi-scale gradational-order fusion framework to make full advantages of multi-scale representations incorporating with gradational-order characteristics of BUS images for breast lesions classification. Specifically, we first construct a spatial context aggregation module to generate multi-scale context representations from the original BUS images. Subsequently, multi-scale representations are efficiently fused in feature fusion block that is armed with special fusion strategies to comprehensively capture morphological characteristics of breast lesions. To better characterize complex textures and enhance non-linear modeling capability, we further propose isotropous gradational-order feature module in the feature fusion block to learn and combine multi-order representations. Finally, these multi-scale gradational-order representations are utilized to perform prediction for the malignant potential of breast lesions.

Results: The proposed model was evaluated on three open datasets by using 5-fold cross-validation. The experimental results (Accuracy: 85.32%, Sensitivity: 85.24%, Specificity: 88.57%, AUC: 90.63% on dataset A; Accuracy: 76.48%, Sensitivity: 72.45%, Specificity: 80.42%, AUC: 78.98% on dataset B) demonstrate that the proposed method achieves the promising performance when compared with other deep learning-based methods in BUS classification task.

Conclusions: The proposed method has demonstrated a promising potential to predict malignant potential of breast lesion using ultrasound image in an end-to-end manner.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmpb.2023.107346DOI Listing

Publication Analysis

Top Keywords

malignant potential
16
potential breast
16
breast lesions
16
bus images
16
multi-scale gradational-order
12
breast
9
breast lesion
8
gradational-order fusion
8
fusion framework
8
complex textures
8

Similar Publications

Background: Trastuzumab deruxtecan (T-DXd) has shown promising activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and central nervous system (CNS) involvement. In this updated meta-analysis, we explore the effectiveness of T-DXd in a large subset of patients with HER2-positive BC and CNS disease.

Methods: A systematic search was made on September 16th, 2024, for studies investigating T-DXd in the scenario of HER2-positive BC and brain metastases (BMs) and/or leptomeningeal disease (LMD).

View Article and Find Full Text PDF

Occult collision tumor of the gastroesophageal junction comprising adenocarcinomas with distinct molecular profiles.

Cancer Genet

January 2025

Department of Pathology and Laboratory Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA; Rutgers Cancer Institute, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.

Collision tumors, characterized by the coexistence of two unique neoplasms in close approximation, are rare and pose diagnostic challenges. This is particularly true when the unique neoplasms are of the same histologic type. Here we report such a case where comprehensive tumor profiling by next generation sequencing (NGS) as well as immunohistochemistry revealed two independent adenocarcinomas comprising what was initially diagnosed as a single adenocarcinoma of the gastroesophageal (GEJ) junction.

View Article and Find Full Text PDF

Reply to: Concerns on Potential Risk of Roxadustat in Promoting Tumor Progression: Double-Edged Sword of Hypoxia-Inducible Factor-1α Activation.

J Clin Oncol

January 2025

George M. Rodgers, MD, PhD, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; and Jeffrey A. Gilreath, PharmD, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, Department of Pharmacy, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

View Article and Find Full Text PDF

Colorectal cancer (CRC) remains a major global health burden, being one of the most prevalent cancers with high mortality rates. Despite advances in conventional treatment modalities, patients with metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC.

View Article and Find Full Text PDF

An Albumin-Photosensitizer Supramolecular Assembly with Type I ROS-Induced Multifaceted Tumor Cell Deaths for Photodynamic Immunotherapy.

Adv Sci (Weinh)

January 2025

Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates, State Key Laboratory of Luminescent Materials and Devices, School of Materials Science and Engineering, AIE Institute, South China University of Technology, Guangzhou, 510640, China.

Photodynamic therapy holds great potentials in cancer treatment, yet its effectiveness in hypoxic solid tumor is limited by the oxygen-dependence and insufficient oxidative potential of conventional type II reactive oxygen species (ROS). Herein, the study reports a supramolecular photosensitizer, BSA@TPE-BT-SCT NPs, through encapsulating aggregation-enhanced emission photosensitizer by bovine serum albumin (BSA) to significantly enhance ROS, particularly less oxygen-dependent type I ROS for photodynamic immunotherapy. The abundant type I ROS generated by BSA@TPE-BT-SCT NPs induce multiple forms of programmed cell death, including apoptosis, pyroptosis, and ferroptosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!